Charing Cross Hospital pioneers new implant treatment for sleep apnoea
Charing Cross Hospital in London has become one of the earliest adopters of an innovative implant treatment for obstructive sleep apnoea, a condition that affects millions of people across the UK. The hospital, part of Imperial College Healthcare NHS Trust, is now offering the procedure to selected patients who have struggled with standard therapies. This marks a significant step forward in the management of a disorder that can severely impact quality of life and long-term health.
The device, a small implant placed under the skin of the chest, works by stimulating the nerve that controls the tongue and airway muscles during sleep. For patients with moderate to severe obstructive sleep apnoea who cannot tolerate continuous positive airway pressure (CPAP) machines, this implant offers a new lease on life. While the technology has been available in a handful of specialist centres abroad, its introduction at a major NHS trust signals a broader push to bring surgical solutions into mainstream sleep medicine.
Details of the specific device model have not been disclosed by the trust, but the general mechanism involves a nerve stimulator that senses breathing patterns and delivers mild electrical pulses to keep the airway open. Patients undergo an overnight sleep study to confirm candidacy, followed by a surgical procedure that typically takes a few hours. Recovery is relatively quick, with the device activated after a healing period of several weeks.
How the implant works and who it helps
The implant treatment is not for everyone. It is designed for patients with moderate to severe obstructive sleep apnoea who have not responded to or cannot tolerate CPAP therapy. CPAP, which uses a mask to deliver pressurised air, remains the gold standard for sleep apnoea. But adherence rates are notoriously low. Studies suggest that between 30 and 50 per cent of patients stop using CPAP within the first year due to discomfort, claustrophobia or noise.
For these individuals, the implant offers an alternative. The device is implanted just below the collarbone, with a thin lead threaded to the hypoglossal nerve in the neck. A separate sensing lead monitors breathing patterns. When the patient breathes in during sleep, the stimulator sends a gentle pulse that moves the tongue forward and stiffens the airway, preventing collapse. The patient does not feel the stimulation once asleep.
Candidates are typically assessed through a combination of sleep studies, upper airway examination, and body mass index criteria. The procedure is carried out under general anaesthesia and patients usually go home the same day or after an overnight stay. Long-term follow-up involves programming adjustments and battery replacement every seven to ten years.
The scale of the problem: 'I stop breathing 47 times an hour'
The personal toll of sleep apnoea is captured in a related story that has resonated widely. A patient quoted in recent reports said: "I stop breathing 47 times an hour when I sleep – there are millions who might be just like me." That figure, though specific to one individual, illustrates the severity that many face. Each pause in breathing can last from ten seconds to over a minute, causing oxygen levels to drop and the brain to briefly wake the person to restart breathing. The result is fragmented, unrefreshing sleep and daytime exhaustion.
Obstructive sleep apnoea is linked to a higher risk of hypertension, heart disease, stroke, type 2 diabetes, and road traffic accidents due to drowsy driving. The NHS estimates that around 1.5 million adults in the UK have moderate to severe sleep apnoea, but many remain undiagnosed. The condition is more common in men, people who are overweight, and those over 40. However, it can affect anyone.
The patient's story highlights the hidden nature of the disorder. Bed partners may notice loud snoring and gasping, but the person themselves often has no idea they are stopping breathing. Home sleep tests and overnight hospital studies are used to diagnose the condition, but waiting lists can be long. The implant treatment, though not a cure, offers a way to effectively manage the condition without a mask.
Broader progress in sleep apnoea care
Alongside the implant news, there are signs that the NHS is making gains in sleep apnoea services overall. Royal Papworth Hospital in Cambridge, a specialist centre for sleep disorders, reported cutting waiting times for sleep apnoea assessment by 10 per cent in June 2025, making it the top performer in NHS East England. That improvement came through streamlining referral pathways, increasing staffing, and expanding home testing capacity.
Royal Papworth is also involved in a research study exploring combined therapy treatment for obstructive sleep apnoea. The study, details of which are still emerging, aims to test whether pairing an implant with targeted lifestyle interventions or other devices can improve outcomes further. This kind of integrated approach could one day become the norm, especially for patients with complex or resistant cases.
The waiting time reduction at Royal Papworth is notable because sleep apnoea services have historically suffered from underinvestment. With rising awareness and diagnosis rates, the need for faster access to care is acute. The implant treatment, though costly upfront, may ultimately reduce long-term healthcare utilisation by preventing complications and improving adherence.
Why it matters: a shift in how we treat sleep apnoea
The significance of Charing Cross Hospital's early adoption goes beyond one trust offering a new gadget. It signals a fundamental shift in the treatment paradigm for obstructive sleep apnoea. For two decades, the conversation has been dominated by CPAP: patients either tolerate it or they do not. Those who cannot use CPAP have had limited options, often stuck with oral appliances or positional therapy that offer marginal benefit. Surgery, such as uvulopalatopharyngoplasty, has inconsistent results and significant morbidity.
The implant represents what specialists call a third line of therapy, but its real promise is in becoming a second line. As more hospitals acquire the technology and surgical teams gain experience, the implant could move from a niche offering to a standard option discussed with every patient who fails CPAP. This is not just about convenience. It is about equity of access. Currently, patients in London and Cambridge may have access to implant treatment, while those in other regions do not. Scaling up the service will require NHS England to make commissioning decisions that weigh upfront surgical costs against long-term savings from reduced cardiovascular events and improved productivity.
Another angle often overlooked is the psychological impact of wearing a CPAP mask. Many patients report feeling self-conscious, leading to relationship strain or avoidance of travel. The implant is invisible once healed, which can dramatically improve adherence and quality of life. From a public health perspective, any therapy that reduces the burden of untreated sleep apnoea – fragmented sleep, morning headaches, cognitive fog – is a net positive. Charing Cross is helping to build the evidence base that will determine whether the NHS adopts this treatment more widely.
What happens next
Charing Cross Hospital is expected to publish outcome data from its initial cohort of patients within the next twelve months. That data will be crucial for other trusts considering whether to invest in the surgical equipment and training needed. The implant manufacturer, meanwhile, is likely pursuing further regulatory approvals and refinements to make the device smaller and more durable.
For patients struggling with sleep apnoea, the message is one of hope. If you have tried CPAP and found it impossible to use, an implant may eventually become available at a hospital near you. But there are hurdles: patient selection is rigorous, and not everyone will be a candidate. The procedure is also not yet available across all NHS regions, so travel may be required.
In the meantime, the stories of individuals like the patient who stops breathing 47 times an hour serve as a powerful reminder of why innovation matters. Sleep apnoea is not just about snoring. It is a serious medical condition that can shorten lives. Charing Cross Hospital's early adoption of implant treatment is a step towards a future where effective, discreet, and scalable options exist for every patient who needs them.
